Activities of analogs GKD4, GKD6 and GKD9.

(A, left graphs) Dose-response of the inhibitory activities of GKD4, GKD6 and GKD9 against interactions of HCMV UL50-UL53 (black) or the UL30 peptide (P30)-UL42 (counter screen, red) in HTRF assays. (A, right graphs). The antiviral activity of each compound against WT HCMV was assessed at 6 dpi with an automated plaque reduction assay (filled circles). Cytotoxicity of each compound was tested in parallel (filled squares). For both left and right graphs, error bars represent standard deviations from three independent experiments. Where no error bars are seen, the standard deviations were too small to be visible. (B) HTRF assays of GKD4, GKD6, and GKD9 for inhibition of interactions of WT UL53 with either WT or the indicated substitution mutants of UL50 (left graphs) or WT UL50 with either WT or the indicated substitution mutants of UL53 (right graphs). For both left and right graphs, error bars represent standard deviations from three independent experiments. Where no error bars are seen, the standard deviations were too small to be visible.

(PDF)